Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
30 oct. 2023 07h30 HE
|
Reviva Pharmaceuticals
- Successfully met primary endpoint; brilaroxazine 50 mg delivered a statistically significant and clinically meaningful 10.1-point reduction in Positive and Negative Syndrome Scale (PANSS) total...
Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia
25 sept. 2023 06h00 HE
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
07 sept. 2023 06h00 HE
|
Reviva Pharmaceuticals
CUPERTINO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...
Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia
17 août 2023 06h00 HE
|
Reviva Pharmaceuticals
- 402 patients completed enrollment across multiple sites in the US, Europe, and Asia – - Topline data for Phase 3 RECOVER study expected in October 2023 - - Completion of 1-year open-label...
Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights
14 août 2023 16h01 HE
|
Reviva Pharmaceuticals
- Topline data for global pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected in October 2023 - - Completion of 1-year open-label extension clinical trial for brilaroxazine...
Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in August
31 juil. 2023 08h00 HE
|
Reviva Pharmaceuticals
CUPERTINO, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals to be Added to Russell Microcap® Index
26 juin 2023 06h00 HE
|
Reviva Pharmaceuticals
CUPERTINO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia
22 juin 2023 06h00 HE
|
Reviva Pharmaceuticals
- Enrollment ongoing at multiple sites in the US, Europe, and Asia - - Multifaceted activity of serotonin-dopamine stabilizer brilaroxazine supports potential for improvement in schizophrenia...
Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in June
15 juin 2023 06h00 HE
|
Reviva Pharmaceuticals
CUPERTINO, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...
Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research Archives
25 mai 2023 06h00 HE
|
Reviva Pharmaceuticals
Brilaroxazine, a novel serotonin-dopamine modulator with multifaceted activities has the potential to treat idiopathic pulmonary fibrosis (IPF) Brilaroxazine improved survival and lung function,...